Overview

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Status:
Unknown status

Trial end date:
2017-05-01

Target enrollment:

Participant gender:

Summary

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in patients with Chronic GT1 or GT4 HCV infection and autoimmune disease

Phase:

Phase 4

Details

Lead Sponsor:

Peter J. Ruane, M.D., Inc.

Collaborator:

Gilead Sciences

Treatments:

Ledipasvir
Ledipasvir, sofosbuvir drug combination
Sofosbuvir